Dr. George M. Cornett, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 368
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Indiana University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
IN license 01038555
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Community Hospital East Indianapolis, IN
- Franciscan Health Indianapolis Indianapolis, IN
- Community Hospital South, Inc. Indianapolis, IN
- Columbus Regional Hospital Columbus, IN
- Johnson Memorial Hospital Franklin, IN
Medical groups
- Franciscan Physician Network (1,170 clinicians)
- American Health Network of Indiana LLC (208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 368
- Services billed
- 2,808
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 693 | 283 |
| Established patient office or other outpatient visit, 30-39 minutes | 552 | 276 |
| Established patient office or other outpatient visit, 20-29 minutes | 220 | 164 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 219 | 219 |
| Administration of influenza virus vaccine | 129 | 128 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 122 | 122 |
| Urinalysis, manual test | 43 | 37 |
| Automated urinalysis test | 41 | 32 |
| Dxa bone density measurement of hip, pelvis, spine | 39 | 39 |
| Transitional care management services for problem of at least moderate complexity | 35 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $108 in total to this clinician.
| Abbott Laboratories | $40.44 |
|---|---|
| Exact Sciences Corporation | $36.98 |
| Medtronic, Inc. | $15.40 |
| Organon LLC | $15.23 |
| Food and Beverage | $108 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $354,908 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - Study name not reported
Novo Nordisk As - A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company · Recruiting · NCT06566170 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.